MAIA-2021-029 / MAIA Biotech - LARVOL DELTA

MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program (Businesswire) - "MAIA Biotechnology, Inc...announced its second broad provisional patent application covering the composition of matter for a new telomere-targeting molecule....MAIA has nominated a new molecular entity candidate (designated as MAIA-2021- 029) for further advancement into preclinical GLP-toxicity and other studies, and may advance this candidate into human clinical trials upon completion of the required preclinical evaluations. The patent titled 'TUMOR REDOX-ACTIVATED 6-THIOPURINE CONTAINING DIMER COMPOUNDS' further adds to MAIA’s Telomere-Targeting Molecule Program..."

Patent • Oncology